Sunovion Announces FDA Filing Acceptance of Resubmitted New Drug Application for Apomorphine Sublingual Film

January 2, 2020— Sunovion Pharmaceuticals, Inc. issued a press release announcing that its New Drug Application (NDA) for apomorphine sublingual film (APL-130277) has been accepted by the U.S. Food and Drug Administration. This on-demand treatment is being developed for ALL types of OFF episodes. The expected action date by the FDA is May 21, 2020.
Read More,

Contact UsTerms Of UsePrivacy Policy

The Parkinson Alliance is a nonprofit, tax-exempt charitable organization under section 501(c)(3) of the Internal Revenue Code. Donations are tax-deductible as allowed by law. Copyright © 2020 The Parkinson Alliance. All rights reserved.